Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Currently, there is no pharmacological intervention for mild symptomatic obstructive sleep
disordered breathing (SDB) in the form of loud habitual snoring, inspiratory flow limitation
(i.e. upper airway resistance syndrome), or mild sleep apnea. Here the investigators study
the effect on SDB of stimulating pharyngeal muscles during sleep with AD036. The key
hypothesis of the study is that AD036 is superior to placebo on self-reported and objective
measures of SDB severity.